A Clinical Discovery.
A Repeatable Intervention.
A Potential Technology Platform.
Human signal · Randomized sham-controlled proof of concept · Repeatable clinical protocol · Technology translation opportunity
Where the Question Began
The Origin
It started with an unexpected clinical observation.
While treating an older patient for a specific non-pain-related complaint, I observed something unexpected: her functional performance appeared to improve as well.
That observation was something we could test.
From Question to Signal
Putting the Observation to the Test
The clinical observation became the basis for a randomized, sham-controlled academic study in 40 elderly participants (mean age 84 years), designed to investigate whether the observed functional response could be reproduced under controlled conditions.
The study provided an initial controlled signal supporting the original clinical observation. Conducted as part of an osteopathy thesis, it represents an early proof of concept that now requires independent validation.
More importantly, the findings suggested that what we were observing might extend beyond pain alone.
An initial signal, not a conclusion.
n=40 · Mean age 84 · Randomized 20/20 · Sham-controlled · Single intervention · Functional assessment 5 min pre/post
Functional Mobility
Completion time
Lower-limb functional performance
completion time
Lower-limb function
repetitions in 30 sec
Significant between-group differences in change were observed across all three functional measures (TUG p < .001 · TCS p = .003 · 30-sec CS p < .001).
Why This Finding Mattered
CONVENTIONAL UNDERSTANDING
Age-related mobility limitations are commonly addressed through exercise, strength and balance training, rehabilitation, and other approaches that typically aim to improve function over time.
WHAT WE OBSERVED
Following a single intervention, participants showed immediate changes in functional performance, with significantly greater improvements than observed in the sham group.
Beyond the Signal
The Question that Remained
What followed was years of clinical investigation, further education and scientific research, looking for an explanation that could connect what we were observing.
No existing explanation we explored fully accounted for what we were observing. Over time, the observations began to point toward a hypothesis of our own.
The original question remained: Why does this happen?
That hypothesis led to a new treatment approach.
From Hypothesis to Practice
The hypothesis led to a new way of identifying and addressing what we believe may be contributing to persistent symptoms.
Applied in clinical practice, the approach has produced encouraging outcomes across patients with different persistent complaints, including patients for whom previous treatments had provided insufficient or temporary relief.
Importantly, the treatment follows a repeatable underlying protocol across different clinical presentations.
A Repeatable Treatment Approach
These outcomes are clinical observations and have not yet been established in controlled studies.
A Second Pattern Emerged
As the treatment was applied repeatedly in clinical practice, another pattern emerged: the time before symptoms returned varied.
Rather than dismissing this variability, it became a new subject of investigation.
Repeated clinical observation eventually pointed to a potential factor influencing the persistence of the response, opening a distinct line of development.
The Response Returned, Its Duration Varied
A new question had become a new opportunity.
From Insight to Prototype
What began as a recurring clinical observation gradually developed into a new working hypothesis. Through continued investigation and refinement, that hypothesis was translated into an early MVP.
The prototype has not yet undergone formal validation. Early observations, however, are encouraging and provide a basis for structured testing.
An Early MVP
The next step is validation.
From Discovery To Validation
What began as a clinical discovery has evolved into two distinct pathways, each with its own questions, opportunities and route to validation.
One Clinical Origin, Two Innovation Pathways.
TECHNOLOGY TRANSLATION
Translate the Underlying Principle
1
Determine whether the critical elements of the discovery can be translated from a founder-led manual treatment into a standardized technological approach.
Define critical parameters
Engineering feasibility
Technology prototype
Manual vs. technology validation
A Distinct Opportunity
The emerging MVP opens a second technological direction, with potential for distinct IP protection, different applications and a development pathway of its own.
Subject to validation, this could open opportunities for licensing, strategic partnership or potentially a separate venture.
2
EMERGING TECHNOLOGY
Validate the Second Innovation
Determine whether the newly identified factor influencing the persistence of the clinical response can be reproduced and validated through the early MVP.
MVP refinement
Technical validation
Reproducibility testing
Independent IP assessment
From Validation To Scale
The original clinical discovery may extend beyond the problem it first emerged from.
The underlying principle has since been observed across different clinical contexts, suggesting that its relevance may not be limited to a single indication or application.
If independently validated and successfully translated into technology, this could provide the foundation for a broader therapeutic platform.
The Platform Opportunity
The Venture Opportunity
Building the Evidence. Engineering the Opportunity.
FLORYQ is moving from clinical discovery toward systematic validation and technology development.
The next phase brings clinical research, engineering, IP strategy and venture development together, with the goal of determining which pathways can develop into reproducible, protectable and scalable medical technologies.
We are looking for the right partners to help take these opportunities forward.